Anti-CEAM3/ CD66d/ CEACAM3 monoclonal antibody
Anti-CEAM3/ CD66d/ CEACAM3 antibody for FACS & in-vivo assay
Go to CD66d/CEACAM3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T21890-Ab-1/ GM-Tg-hg-T21890-Ab-2 | Anti-Human CD66d/CEACAM3 monoclonal antibody | Human |
GM-Tg-rg-T21890-Ab-1/ GM-Tg-rg-T21890-Ab-2 | Anti-Rat CD66d/CEACAM3 monoclonal antibody | Rat |
GM-Tg-mg-T21890-Ab-1/ GM-Tg-mg-T21890-Ab-2 | Anti-Mouse CD66d/CEACAM3 monoclonal antibody | Mouse |
GM-Tg-cynog-T21890-Ab-1/ GM-Tg-cynog-T21890-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD66d/CEACAM3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T21890-Ab-1/ GM-Tg-felg-T21890-Ab-2 | Anti-Feline CD66d/CEACAM3 monoclonal antibody | Feline |
GM-Tg-cang-T21890-Ab-1/ GM-Tg-cang-T21890-Ab-2 | Anti-Canine CD66d/CEACAM3 monoclonal antibody | Canine |
GM-Tg-bovg-T21890-Ab-1/ GM-Tg-bovg-T21890-Ab-2 | Anti-Bovine CD66d/CEACAM3 monoclonal antibody | Bovine |
GM-Tg-equg-T21890-Ab-1/ GM-Tg-equg-T21890-Ab-2 | Anti-Equine CD66d/CEACAM3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T21890-Ab-1/ GM-Tg-hg-T21890-Ab-2; GM-Tg-rg-T21890-Ab-1/ GM-Tg-rg-T21890-Ab-2; GM-Tg-mg-T21890-Ab-1/ GM-Tg-mg-T21890-Ab-2; GM-Tg-cynog-T21890-Ab-1/ GM-Tg-cynog-T21890-Ab-2; GM-Tg-felg-T21890-Ab-1/ GM-Tg-felg-T21890-Ab-2; GM-Tg-cang-T21890-Ab-1/ GM-Tg-cang-T21890-Ab-2; GM-Tg-bovg-T21890-Ab-1/ GM-Tg-bovg-T21890-Ab-2; GM-Tg-equg-T21890-Ab-1/ GM-Tg-equg-T21890-Ab-2 |
Products Name | Anti-CD66d/CEACAM3 monoclonal antibody |
Format | mab |
Target Name | CD66d |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CD66d benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CEAM3/ CD66d/ CEACAM3 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAP000486 | Human CEACAM3 Adenovirus plasmid |
ORF Viral Vector | vGMAP000486 | Human CEACAM3 Adenovirus particle |
Target information
Target ID | GM-T21890 |
Target Name | CD66d |
Gene ID | 1084,707824 |
Gene Symbol and Synonyms | CD66D,CEA,CEACAM3,CGM1,W264,W282 |
Uniprot Accession | P40198 |
Uniprot Entry Name | CEAM3_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Diagnostics Biomarker, Immuno-oncology Target |
Disease | Cancer |
Gene Ensembl | ENSG00000170956 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: CD66d, gene name: CEACAM3, also named as CD66D, CEA, CGM1, W264, W282. This gene encodes a member of the family of carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), which are used by several bacterial pathogens to bind and invade host cells. The encoded transmembrane protein directs phagocytosis of several bacterial species that is dependent on the small GTPase Rac. It is thought to serve an important role in controlling human-specific pathogens by the innate immune system. Alternatively spliced transcript variants have been described. [provided by RefSeq, Mar 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.